GPT and portal hypertension: No patient developed de novo clinical cirrhosis or portal hypertension, and all patients who experienced an ALT rise resulting in loss of biochemical remission during the study follow‐up period subsequently received changes to their medication regime, with 1 patient starting de novo corticosteroid therapy and the remaining having their dosage increased.